BR112022018034A2 - Mitigação de interferência alvo no ensaio de anticorpo antifármaco - Google Patents

Mitigação de interferência alvo no ensaio de anticorpo antifármaco

Info

Publication number
BR112022018034A2
BR112022018034A2 BR112022018034A BR112022018034A BR112022018034A2 BR 112022018034 A2 BR112022018034 A2 BR 112022018034A2 BR 112022018034 A BR112022018034 A BR 112022018034A BR 112022018034 A BR112022018034 A BR 112022018034A BR 112022018034 A2 BR112022018034 A2 BR 112022018034A2
Authority
BR
Brazil
Prior art keywords
mitigation
antibody assay
drug antibody
methods
systems
Prior art date
Application number
BR112022018034A
Other languages
English (en)
Inventor
Chen Jihua
Kendra Kimberly
Torri Albert
Oliveira Sumner Giane
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112022018034A2 publication Critical patent/BR112022018034A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

MITIGAÇÃO DE INTERFERÊNCIA ALVO NO ENSAIO DE ANTICORPO ANTIFÁRMACO. A presente invenção refere-se a métodos e sistemas para detectar, quantificar ou caracterizar anticorpos antifármaco que são induzidos pela administração de produtos farmacêuticos. Os métodos e sistemas incluem o uso de um parceiro de ligação de um alvo e/ou um cofator para melhorar a detecção de anticorpos antifármaco em amostras de soro na presença de alvos solúveis com base na ligação ao alvo competitiva. Os métodos e sistemas também incluem o uso de imunodepleção para melhorar a detecção.
BR112022018034A 2020-03-17 2021-03-16 Mitigação de interferência alvo no ensaio de anticorpo antifármaco BR112022018034A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990681P 2020-03-17 2020-03-17
PCT/US2021/022623 WO2021188587A1 (en) 2020-03-17 2021-03-16 Target interference mitigation in anti-drug antibody assay

Publications (1)

Publication Number Publication Date
BR112022018034A2 true BR112022018034A2 (pt) 2022-10-18

Family

ID=75581604

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018034A BR112022018034A2 (pt) 2020-03-17 2021-03-16 Mitigação de interferência alvo no ensaio de anticorpo antifármaco

Country Status (11)

Country Link
US (1) US20210293811A1 (pt)
EP (1) EP4121775A1 (pt)
JP (1) JP2023517751A (pt)
KR (1) KR20220156023A (pt)
CN (1) CN115667935A (pt)
AU (1) AU2021237564A1 (pt)
BR (1) BR112022018034A2 (pt)
CA (1) CA3177634A1 (pt)
IL (1) IL296424A (pt)
MX (1) MX2022011336A (pt)
WO (1) WO2021188587A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3821255B1 (en) * 2018-07-10 2024-08-28 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
WO2024015418A1 (en) * 2022-07-13 2024-01-18 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
CN116699147A (zh) * 2023-08-04 2023-09-05 军科正源（北京）药物研究有限责任公司 检测总IgE含量的方法以及相关试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022001A1 (en) * 2007-08-16 2009-02-19 Novartis Ag Improvement of drug tolerance in immunogenicity testing
EP3821255B1 (en) * 2018-07-10 2024-08-28 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay

Also Published As

Publication number Publication date
WO2021188587A1 (en) 2021-09-23
KR20220156023A (ko) 2022-11-24
IL296424A (en) 2022-11-01
AU2021237564A1 (en) 2022-10-06
EP4121775A1 (en) 2023-01-25
CA3177634A1 (en) 2021-09-23
CN115667935A (zh) 2023-01-31
MX2022011336A (es) 2022-10-07
US20210293811A1 (en) 2021-09-23
JP2023517751A (ja) 2023-04-26

Similar Documents

Publication Publication Date Title
BR112022018034A2 (pt) Mitigação de interferência alvo no ensaio de anticorpo antifármaco
Waritani et al. An ELISA protocol to improve the accuracy and reliability of serological antibody assays
Wang et al. An immunomagnetic-bead-based enzyme-linked immunosorbent assay for sensitive quantification of fumonisin B1
Hnasko et al. A rapid method to improve protein detection by indirect ELISA
BR112015022844A8 (pt) método para determinar a presença ou ausência de anticorpos específicos do doador em uma amostra biológica, sistema e kit para praticar o mesmo
JP6756611B2 (ja) 中和抗体を検出するための競合リガンド結合アッセイ
BR112015032960A8 (pt) imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
Micheli et al. Production of antibodies and development of highly sensitive formats of enzyme immunoassay for saxitoxin analysis
Wharton et al. Quantification of saxitoxin in human blood by ELISA
Terato et al. Preventing further misuse of the ELISA technique and misinterpretation of serological antibody assay data
EA202190237A1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
ATE412179T1 (de) Nachweis von arzneistoffen der methamphetamingruppe
BR112018005812A2 (pt) ?método de imunoensaio para a detecção de um analito, kit de reagentes para detectar um analito por um imunoensaio e uso de um parceiro de ligação marcador-específico?
Sassolas et al. Improvement of the efficiency and simplification of ELISA tests for rapid and ultrasensitive detection of okadaic acid in shellfish
Nielsen et al. Fluorescence polarization assay for the diagnosis of bovine brucellosis: adaptation to field use
JPWO2018047793A1 (ja) 腫瘍マーカーの測定方法及び測定試薬
Dixon-Holland et al. Competitive direct enzyme-linked immunosorbent assay for detection of sulfamethazine residues in swine urine and muscle tissue
MX2021013519A (es) Ensayos de union de ligandos competitivos mejorados.
Zhao et al. AlphaLISA for detection of staphylococcal enterotoxin B free from interference by protein A
EA201370030A1 (ru) Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
CN109477832A (zh) 甲状腺球蛋白的测定方法及测定试剂
Iha et al. Zeptomole detection of an enzyme by a simple colorimetric method
Darwish et al. Development of new ELISA with high sensitivity and selectivity for bioanalysis of bevacizumab: a monoclonal antibody used for cancer immunotherapy
Alhabbab et al. Amplifying lateral flow assay signals for rapid detection of COVID‐19 specific antibodies
Weller et al. Development of a direct competitive microcystin immunoassay of broad specificity